Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
|
|
- Jean Arnold
- 6 years ago
- Views:
Transcription
1 STUDY Sentinel Lymph Node Biopsy in Patients With Thin Melanoma Julie B. Lowe, MD; Eva Hurst, MD; Jeffrey F. Moley, MD; Lynn A. Cornelius, MD Objective: To define the percentage of positive sentinel lymph node biopsies and identify risk factors for the presence of lymph node disease in patients with melanomas less than or equal to 1 mm in depth. Design: Retrospective chart review. Setting: Washington University School of Medicine and Barnes-Jewish Hospital, St Louis, Mo, a melanoma referral center with outpatient surgical care. Patients: Forty-six patients with melanomas less than or equal to 1 mm in depth undergoing sentinel lymph node biopsy at our institution between 1996 and Results: The procedure was well tolerated and there were no reported complications. Of the 46 patients, 3 (7%) (95% exact confidence interval, 1.3%-17.8%) were found to have positive sentinel lymph nodes or micrometastatic disease. The finding of a positive sentinel lymph node was associated with a Clark level of III or more (P.07). Conclusions: Conclusions from this study are limited by the small sample size. The results of our study suggest that sentinel lymph node biopsy of patients with melanomas less than or equal to 1 mm in depth may be indicated when the Clark level is III or more. Arch Dermatol. 2003;139: From the Divisions of Dermatology (Drs Lowe, Hurst, and Cornelius) and Surgical Oncology (Dr Moley), Washington University School of Medicine, St Louis, Mo. The authors have no relevant financial interest in this article. MELANOMA HAS been increasing in incidence in the United States since the mid-1970s. 1 In the 1930s, the lifetime incidence of melanoma was 1 in For persons born in 2002, the lifetime incidence of invasive melanoma is 1 in 67. For the year 2002, it was estimated that approximately people would be diagnosed as having invasive melanoma; another will be diagnosed as having melanoma in situ. 3 Approximately 7400 people are expected to die of melanoma in The greatest increase in diagnosis has been in thin tumors, or lesions less than 1 mm thick. 4 Melanoma prognosis is inversely proportional to tumor thickness, or Breslow level, 5-8 and level of invasion. 9 Tumors less than 1 mm in depth represent lower-risk disease 10 and have a greater than 90% 5-year survival, 11 while the survival rate for tumors with a depth of less than 0.75 mm is greater than 95%. 12 However, thin lesions retain the ability to recur and metastasize Lesions less than 0.75 mm in depth have a reported rate of distant metastasis in the range of 1% or 2% to 5.5%. 14,16-18 Guitart et al recently reported 2 cases of metastases from primary tumors of melanoma in situ. 19 For patients with stage I and stage II melanoma, sentinel lymph node status is the most significant prognostic factor for recurrence and disease-specific survival. 20 Lymphatic mapping with sentinel lymph node biopsy (SLNB) allows for early detection of metastatic disease with minimal morbidity. Sentinel lymph node biopsy is an outpatient procedure, and paresthesias and lymphedema associated with traditional elective lymph node dissections rarely occur. Sentinel lymph node biopsy has been recommended for patients with lesions less than 1 mm thick that are at least Clark level IV or that are ulcerated. 20,21 In one series of 230 patients with tumors less than 1.5 mm, 4.8% had a positive sentinel node identified by conventional histologic analysis, primarily routine hematoxylin-eosin staining. 20 Likewise, 4.7% of patients with lesions less than 1 mm, but with ulceration or a Clark level of IV or greater, had a positive sentinel node. 20 A second study of a series of 71 patients with lesions less than 1 mm in depth reported a rate of sentinel lymph node metastasis of 5.6%. 22 In patients with lesions less than 1.4 mm in depth and a positive sentinel node, additional positive nodes are virtually never found on completion lymphadenectomy. 23,24 617
2 Controversy exists regarding the utility of SLNB for primary tumors that are nonulcerated and less than 1 mm in depth, particularly those with a Clark level of II or III. According to Dubois et al, 21 SLNB is inappropriate for nonulcerated lesions 0.75 mm or less in depth, with a Clark level of II or III. In one study of 75 persons undergoing SLNB with primary tumors less than 0.9 mm in depth, Statius Muller et al 25 found that none of the sampled nodes was positive. It has been demonstrated, however, that patients with a positive sentinel node are more likely to have a primary lesion that is axially located, thick, or ulcerated. 20 In patients with tumors of similar depth, axial location has been associated with a worsened prognosis, as has male sex. 16 Axial location has been correlated with metastasis in thin melanomas as well. 14,19 Ulceration is believed to be related to rapid tumor growth, increased tumor doubling time, compromised blood supply, 12 and worsened prognosis. 11 Although rarely seen in tumors thinner than 1 mm, ulceration has, in fact, been correlated with metastases in thin lesions. 26 In tumors thinner than 1 mm, a Clark level of IV or greater is associated with higher rates of metastasis 14 and increased mortality. 13,15,27 Melanomas in the vertical growth phase, or infiltrating into the dermis and subcutaneous tissue, have been reported to have an increased incidence of disease metastasis, 28,29 although conflicting reports exist. 23 Host tumor response may result in histologic evidence of tumor regression and partial destruction of the tumor. 30,31 Clinically, areas of depigmentation within the tumor may be seen Tumor regression may be associated with a worsened prognosis, possibly reflective of more aggressive biological behavior 35 or underestimation of tumor depth. 36 Consequently, in patients with lesions of similar depth, regression has been associated with metastasis and a worsened prognosis, 14,16,18,19,35-39 although these findings have been refuted. 13,15,40-43 Our study was undertaken to describe the incidence of sentinel lymph node metastasis in our patient population, and to identify the risk factors for sentinel node disease in patients with a Breslow depth of less than or equal to 1 mm. METHODS PATIENT DATA Charts of patients treated at Washington University School of Medicine and Barnes-Jewish Hospital, St Louis, Mo, for melanoma between 1996 and 2002 were reviewed for age at diagnosis; tumor location, depth, presence of regression or ulceration, and histologic subtype; methods of treatment; and patient outcome. Permission for this study was obtained from the Human Studies Committee at Washington University School of Medicine under approval No Two hundred fiftyone patients with primary lesions that were less than or equal to 1 mm in depth on original histopathologic examination were treated at our institution during this time. Of the 251 patients with thin tumors, 140 of the original biopsies were performed at outside institutions, then the patients were referred to our institution for definitive management and follow-up. As a routine practice, tissue specimens from outside institutions were reviewed by dermatopathologists at our institution before any management decisions were made. At the time of wide reexcision, 21 of the patients had residual disease at the site of the original primary tumor. The corresponding subjects were excluded from this study. SENTINEL LYMPH NODE BIOPSY A review of 230 subjects with lesions equal to or thinner than 1 mm treated at our institution between July 1, 1996, and August 31, 2002, showed that 46 patients underwent SLNB. In each case, the decision to undergo SLNB was based on the clinical presentation and was made jointly by the physician and the patient. Factors that influenced the decision to have an SLNB included the lesion depth, the Clark level of invasion, and presence of regression or ulceration on histopathologic examination of the primary lesion. In most cases, SLNB was performed at the time of wide local excision, after identification of the sentinel node by means of lymphoscintigraphy. No intraoperative complications were associated with the procedure in any of these patients. Initially described by Morton et al in 1992, 44 the technique of SLNB has been previously reported Briefly, at our institution, once the diagnosis of a melanoma 1 mm or greater in depth or Clark level IV is confirmed on histopathologic examination, the patient returns for a wide excision, lymphatic mapping, and SLNB. Evaluation of the sentinel node begins with injection of a radioactive tracing agent at the site of the resected tumor. After the radioactive agent has been given sufficient time to drain into the nodal basin, the location of the sentinel node is detected by radiography and marked on the patient. This mark, along with a radioactive probe for confirmation in some cases, is used to localize the incision and identify the sentinel node. Before the incision is made, isosulfan blue is injected into the site of the previous resection and allowed to drain to the nodal bed, serving as an additional guide and a confirmation that the correct node has been isolated. The sentinel node is sent to the pathology department for histologic examination. In all cases, sentinel nodes were evaluated by a boardcertified pathologist using standard histologic examination with hematoxylin-eosin staining. In addition, beginning in 2000, all nodes that were negative by histologic examination were also evaluated for micrometastases by immunohistochemical staining, primarily the MART-1 antibody. In all, 25 cases were reviewed by histologic examination alone and 21 cases were reviewed with both histologic examination and immunohistochemistry. STATISTICAL EVALUATION The relationship between sentinel node positivity and age, sex, level of invasion, depth of lesion, tumor regression, and tumor ulceration was analyzed by means of Cox simple regression model. Similar comparisons were made between these variables and death by means of Cox simple regression. The relationships of node positivity and death with lesion location and histogenic subtype were analyzed by means of analysis of variance. All statistical analysis was performed with the Minitab Statistical software package, version 13 (Minitab Inc, State College, Pa). RESULTS A total of 230 subjects with lesions equal to or less than 1 mm thick were included in this study. Of the subjects, 131 were male and 99 were female. The mean age of sub- 618
3 jects was 53.0 years (range, years). Other patient characteristics are listed in Table 1. Consistent with previous data, primary lesions were most commonly located on the trunk in male patients (52.3%) and the extremities in female patients (49.5%). The dominant histologic types of lesions were lentigo maligna and superficial spreading in male subjects (36.6% and 38.2%, respectively) and superficial spreading melanoma in female subjects (50.5%). In all, 59 patients with primary tumors less than or equal to 1 mm in depth were referred for tumor reexcision and SLNB. However, 13 of these patients were excluded from this study, either because the original pathology specimen was not available for review (n=2) or because residual tumor was found at the time of the tumor reexcision, making the true depth of the lesion less definitive (n=11). The study population, therefore, consisted of 46 individuals, 26 men and 20 women, with a mean age of 50 years (range, years). Of those undergoing SLNB, 8 subjects had in situ lesions. The mean lesion depth in the remaining subjects was 0.74 mm. Of the original biopsies, 32 were performed at outside institutions and the patients were subsequently referred to Washington University School of Medicine for definitive treatment. Other patient characteristics are listed in Table 2. TUMOR CHARACTERISTICS Of the patients undergoing SLNB, 15 had tumors with histologic evidence of regression and 1 with ulceration. Fifteen were vertical growth phase melanomas, 15 were in radial growth phase, and 16 did not have the growth phase specified. Twelve of the tumors were Clark level I or II, 19 were level III, and 15 were level IV. Of the 46 subjects undergoing SLNB, 3 (7%) had disease in the sentinel node (95% exact confidence interval, 1.3%-17.8%). Of the 3 patients found to have sentinel node metastases, 2 were male and 1 was female. Two of the subjects had histologic evidence of metastatic lymph node disease, and one subject had immunohistochemical evidence alone. None of the primary lesions with positive sentinel nodes had evidence of regression or ulceration on histopathologic examination. Two of the primary lesions were in the radial growth phase; the growth phase of the third was not designated in the pathological report. Invasion to Clark level III or greater was associated with lymph node metastasis (P=.07), but this did not reach statistical significance because of the small sample size. Table 3 lists other patient information. PATIENT FOLLOW-UP The 3 patients with sentinel node metastases underwent lymph node dissections of the appropriate nodal basin. The completion lymphadenectomies were negative for metastatic disease, and all patients remained disease free. The 43 patients who were not found to have disease in the sentinel node at the time of SLNB remained alive and disease free at last follow-up. Table 1. All Patients With Melanomas Less Than or Equal to 1 mm in Depth All Patients (n = 230) COMMENT Male (n = 131) Female (n = 99) Mean age, y Site of disease, % Head and neck Trunk Extremity Sole Histologic subtype, % Superficial spreading Lentigo maligna Nodular Acral lentiginous Other, not otherwise specified Table 2. Patients With Melanomas Less Than or Equal to 1 mm in Depth Undergoing SLNB All Patients (n = 46) Male (n = 26) Female (n = 20) Mean age, y Site of disease, No. (%) Head and neck 5 (11) 4 (15) 1 (5) Trunk 22 (48) 16 (62) 6 (30) Extremity 18 (39) 5 (19) 13 (65) Sole 1 (2) 1 (4) 0 Histologic subtype, No. (%) Superficial spreading 32 (70) 16 (62) 16 (80) Lentigo maligna 7 (15) 5 (19) 2 (10) Nodular Acral lentiginous 2 (4) 1 (4) 1 (5) Other, not otherwise specified 5 (11) 4 (15) 1 (5) Abbreviation: SLNB, sentinel lymph node biopsy. Table 3. Information for Patients With Melanomas Less Than or Equal to 1 mm in Depth and Positive Sentinel Nodes* Patient Age, y/sex Location Breslow Depth, mm Clark Level 36/F Arm 0.56 III 64/M Back 0.96 III 47/M Arm 0.50 III-IV *All 3 patients: (1) had excisional biopsies for diagnosis, (2) had superficial spreading melanoma histologic subtypes without regression or ulceration, (3) underwent elective lymph node dissection, and (4) were disease free at last follow-up. Melanoma nodal metastasis has been reported to occur as an orderly event, with initial spread to the sentinel node and subsequent progression to other nodes. 47 Sentinel node biopsy, originally described by Morton et al in 1992, 44 is currently recommended for all patients with melanoma tumors greater than 1 mm in depth without clinical evidence of metastasis at the time of diagnosis. In addition, SLNB is presently recommended in lesions less than 1 mm in depth with ulceration or invasion to a 619
4 Clark level of IV or greater. 20,21 Subjects with nodal metastasis detected on SLNB are then advised to undergo completion lymph node dissection and be considered for interferon therapy. Previous studies have reported positive sentinel node rates of 4.7% for patients with lesions 0.76 to 1.49 mm in depth, 19% for lesions 1.51 to 4 mm, and 34% to 36% for lesions greater than 4 mm. 20,48 The benefit of complete lymphadenectomy in patients with melanoma has been debated. Initially, several studies found no overall survival advantage in patients with melanoma who underwent elective lymph node dissection However, subgroup analysis has found that elective lymph node dissection improves survival in selected subgroups, specifically in those younger than 60 years, with lesions 1 to 2 mm in thickness, and particularly in subjects with nonulcerated lesions. 49,50 In addition, in subjects with tumors greater than 1.5 mm in depth and with occult nodal metastases, it has been reported that subjects undergoing immediate elective lymph node dissection have increased survival compared with subjects undergoing nodal dissection after the appearance of clinical disease. 51 In this study, we reviewed the outcomes of 46 subjects with lesions equal to or less than 1 mm in depth undergoing SLNB. Fifteen had tumors with histologic evidence of regression and 1 with ulceration. Fifteen of the tumors were in the vertical growth phase, 15 were in the radial growth phase, and 16 did not have the growth phase specified. Twelve of the tumors were Clark level I or II, 19 were level III, and 15 were level IV. Of the 46 subjects undergoing SLNB, 3 (7%) had disease in the sentinel node (95% exact confidence interval, 1.3%-17.8%). This percentage is slightly higher than that previously reported. 22 All 3 tumors were of the superficial spreading melanoma subtype. Two of the primary tumors were in the radial growth phase, and the growth phase of the third was not designated. None of these subjects had lesions that were ulcerated or regressed on histopathologic evaluation, although the prognostic significance of ulceration in stage I and II melanoma is well recognized. 11 None of the 8 patients with in situ lesions had micrometastatic disease. The only factor predictive of a positive SLNB in these 3 patients was the presence of a Clark level of III or more (P.07). Given the limited number of patients in this study, this did not reach statistical significance. Although this is consistent with previous recommendations of Clark level IV as a criterion for SLNB, our data suggest that in tumors of 1 mm or less, SLNB could be considered for Clark level III lesions. The outcomes of our study were limited by the small size of our study group. Our study substantiates the findings of other groups, where thin melanomas have been demonstrated to have the potential to metastasize to the regional nodal basin. In our experience, SLNB is a useful adjunct to prognosis and treatment in thin melanomas with a Breslow depth of 1 mm or less and a more invasive Clark level, in this case III or more. The results of our study also support the reporting of Clark level for T1 ( 1-mm) melanomas, as included in the new American Joint Committee on Cancer staging for cutaneous melanoma. 11 Our future studies will include comparison of the patient cohort (patients with melanomas 1 mm undergoing SLNB) having positive sentinel nodes and resultant lymphadenectomies with patients having similar tumor depths but not undergoing SLNB, for recurrence-free and overall survival. Accepted for publication November 5, Reprints are not available from the authors. REFERENCES 1. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93: Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin. 2000;50: Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, CA Cancer J Clin. 2002;52: Lipsker DM, Hedelin G, Heid E, Grosshans EM, Cribier BJ. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol. 1999;135: Lane N, Lattes R, Malm J. Clinicopathological correlations in a series of 117 malignant melanomas of the skin of adults. Cancer. 1958;11: Lund RH, Ihnen M. Malignant melanoma: clinical and pathological analysis of 93 cases: is prophylactic lymph node dissection indicated? Surgery. 1955;38: Mehnert JH, Heard JL. Staging of malignant melanoma by depth of invasion. Am J Surg. 1965;110: Petersen NC, Bodenham DC, Lloyd OC. Malignant melanomas of the skin. Br J Plast Surg. 1962;15: Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969; 29: NIH Consensus Statement online. Diagnosis and treatment of early melanoma. 1992;10:1-26. Available at: Accessed October 31, Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: King R, Googe PB, Mihm MC Jr. Thin melanomas. Clin Lab Med. 2000;20: Kelly JW, Sagebiel RW, Clyman S, Blois MS. Thin level IV malignant melanoma: a subset in which level is the major prognostic indicator. Ann Surg. 1985;202: Naruns PL, Nizze JA, Cochran AJ, Lee MB, Morton DL. Recurrence potential of thin primary melanomas. Cancer. 1986;57: Shaw HM, McCarthy WH, McCarthy SW, Milton GW. Thin malignant melanomas and recurrence potential. Arch Surg. 1987;122: Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal thin malignant melanoma: identifying patients at risk. Ann Surg. 1988;208: Woods JE, Soule EH, Creagan ET. Metastasis and death in patients with thin melanomas (less than 0.76 mm). Ann Surg. 1983;198: Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlof B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer. 1994; 73: Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002; 138: Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17: Dubois RW, Swetter SM, Atkins M, et al. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001;137: Bedrosian I, Faries MB, Guerry D, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma ( or=1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7: Thompson JF, Shaw HM. Sentinel node metastasis from thin melanomas with vertical growth phase. Ann Surg Oncol. 2000;7: Joseph E, Brobeil A, Glass F, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol. 1998;5:
5 25. Statius Muller MG, van Leeuwen PA, van Diest PJ, Vuylsteke RJ, Pijpers R, Meijer S. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res. 2001;11: Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15: McCarthy WH, Shaw HM, McCarthy SW, Rivers JK, Thompson JF. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol. 1996; 23: Clark WH Jr, Elder DE, Guerry D, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984;15: Szymik B, Woosley JT. Further validation of the prognostic model for stage I malignant melanoma based on tumor progression. J Cutan Pathol. 1993;20: Clark WH Jr, Ainsworth AM, Bernardino EA, Yang CH, Mihm CM Jr, Reed RJ. The developmental biology of primary human malignant melanomas. Semin Oncol. 1975;2: Reed RJ, Ichinose H, Clark WH Jr, Mihm MC Jr. Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol. 1975;2: Mihm MC Jr, Clark WH Jr, From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med. 1971;284: Mihm MC Jr, Fitzpatrick TB, Brown MM, Raker JW, Malt RA, Kaiser JS. Early detection of primary cutaneous malignant melanoma: a color atlas. N Engl J Med. 1973;289: Mihm MC Jr, Fitzpatrick TB. Early detection of malignant melanoma. Cancer. 1976; 37(1, suppl): Paladugu RR, Yonemoto RH. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg. 1983;118: Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer. 1978;42: Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology. 1990;17: Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123: Sondergaard K, Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I: a study of 486 cases. Virchows Arch A Pathol Anat Histopathol. 1985;408: McLean DI, Lew RA, Sober AJ, Mihm MC Jr, Fitzpatrick TB. On the prognostic importance of white depressed areas in the primary lesion of superficial spreading melanoma. Cancer. 1979;43: Trau H, Rigel DS, Harris MN, et al. Metastases of thin melanomas. Cancer. 1983; 51: Wanebo HJ, Cooper PH, Hagar RW. Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression. Ann Surg. 1985;201: McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology. 1983;7: Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127: Leong SP, Steinmetz I, Habib FA, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg. 1997;132: Van der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probe guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg. 1994;81: Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220: Slingluff CL Jr, Stidham KR, Ricci WM, Stanley WE, Seigler HF. Surgical management of regional lymph nodes in patients with melanoma: experience with 4682 patients. Ann Surg. 1994;219: Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224: Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm): Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7: Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial: WHO Melanoma Programme. Lancet. 1998;351: Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61: Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49: ARCHIVES Web Quiz Winner C ongratulations to the winner of our February quiz, Laxmisha Chandrashekar, MB, BS, junior resident, Department of Dermatology and Venereology, Jawaharlal Institute of Postgraduate Education and Research, Pondicherry, India. The correct answer to our February challenge was reticulohistiocytosis. For a complete discussion of this case, see the Off-Center Fold section in the March ARCHIVES (Caputo R, Marzano AV, Gianotti R. Asymptomatic nodule on the upper lip. Arch Dermatol. 2003;139: ). Be sure to visit the Archives of Dermatology World Wide Web site ( to try your hand at the Interactive Quiz. We invite visitors to make a diagnosis based on selected information from a case report or other feature scheduled to be published in the following month s print edition of the ARCHIVES. The first visitor to our Web editors with the correct answer will be recognized in the print journal and on our Web site and will also receive a free copy of the The Art of JAMA II. 621
SENTINEL LYMPH node (SLN) biopsy has become
COMMENTARY Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement By Kelly M. McMasters, Douglas S. Reintgen, Merrick I. Ross, Jeffrey E. Gershenwald, Michael J. Edwards, Arthur
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationMalignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More informationORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue
More informationSentinel Lymph Node Biopsy for the T1 (Thin) Melanoma: Is It Necessary?
Sentinel Lymph Node Biopsy for the T1 (Thin) Melanoma: Is It Necessary? Maurice Y. Nahabedian, MD Anthony P. Tufaro, MD Paul N. Manson, MD The use of sentinel lymph node biopsy for the T1 melanoma is controversial.
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationNodal staging in localized melanoma. The experience of the Brescia Melanoma Unit
The British Association of Plastic Surgeons (2003) 56, 534 539 Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit Giorgio Manca a, *, Fabio Facchetti b, Claudio Pizzocaro
More informationPatent Blue Dye (P.B.D) tums.ac.ir
80-84 1387 2 66 80 : 30 :.. 1385 1382.. Patent Blue Dye (P.B.D). 48 :. - (%47)13 19 195 17.. :.. : * * 88723410 : email: omranipour@ tums.ac.ir. 4 5. Patent Blue Dye (P.B.D) 6-8 %13. %20 1 2. 3 1992 Morton.
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationPAPER. Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary?
PAPER Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary? Nahel Elias, MD; Kenneth K. Tanabe, MD; Arthur J. Sober, MD; Michele A. Gadd, MD;
More informationBreslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma
Research DOI: 10.6003/jtad.16104a2 Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma Daniela Xhemalaj, MD, Mehdi Alimehmeti, MD, Susan Oupadia, MD, Majlinda Ikonomi, MD, Leart
More informationORIGINAL ARTICLE. (SLN) biopsy is revolutionizing
ORIGINAL ARTICLE Management of Malignant Melanoma of the Head and Neck Using Dynamic Lymphoscintigraphy and Gamma Probe Guided Sentinel Lymph Node Biopsy Grant W. Carlson, MD; Douglas R. Murray, MD; Robert
More information1
www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,
More informationPAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma
PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas
More informationMelanoma of the Skin INTRODUCTION SUMMARY OF CHANGES
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb
More informationMelanoma of the Skin
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb
More informationFive years of sentinel node biopsy for melanoma: the St George s Melanoma Unit experience
The British Association of Plastic Surgeons (2004) 57, 97 104 Five years of sentinel node biopsy for melanoma: the St George s Melanoma Unit experience Adam Topping a, *, Donald Dewar a, Victoria Rose
More informationClinical Practice Guidelines
Clinical Practice Guidelines Clinical Practice Guidelines for Melanoma Douglas Reintgen, MD, et al H. Lee Moffitt Cancer Center & Research Institute These clinical practice guidelines for melanoma have
More informationSentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
More informationLYMPHATIC DRAINAGE PATTERNS OF HEAD AND NECK CUTANEOUS MELANOMA OBSERVED ON LYMPHOSCINTIGRAPHY AND SENTINEL LYMPH NODE BIOPSY
LYMPHATIC DRAINAGE PATTERNS OF HEAD AND NECK CUTANEOUS MELANOMA OBSERVED ON LYMPHOSCINTIGRAPHY AND SENTINEL LYMPH NODE BIOPSY Doris Lin, MD, 1 Benjamin L. Franc, MD, 2 Mohammed Kashani-Sabet, MD, 3 Mark
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationUniversity of Groningen
University of Groningen Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients Faut, Marloes; Wevers, Kevin; van
More informationORIGINAL ARTICLE. Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma
ORIGINAL ARTICLE Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma Cecelia E. Schmalbach, MD; Brian Nussenbaum, MD; Riley S. Rees, MD; Jennifer Schwartz, MD; Timothy
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationNodal Treatment in Melanoma: Snow to MSLT-II
Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,
More informationKatsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe
Akita J Med 36 : 45-52, 2009 45 Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe (Received 22 December 2008, Accepted 15 January 2009)
More informationPolypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern
Polypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern ELIZABETH A. MANCI, M.D., CHARLES M. BALCH, M.D..TARIQ M. MURAD, M.D., PH.D., AND SENG/JAW SOONG, PH.D. Manci, Elizabeth A., Balch, Charles
More informationPatients with thick cutaneous melanoma ( 4 mm) pose a challenge. Prognostic Factors in Patients with Thick Cutaneous Melanoma (> 4 mm)
1049 Prognostic Factors in Patients with Thick Cutaneous Melanoma (> 4 mm) Elizabeth Zettersten, M.D. 1 Richard W. Sagebiel, M.D. 1 James R. Miller III, Ph.D. 1,2 Sreedhar Tallapureddy, M.D. 1 Stanley
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationSentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma
Sentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma S. Ross Patton, MD - PGY III Faculty Mentor: Susan McCammon, MD The University of Texas Medical Branch (UTMB Health) Department of Otolaryngology
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationAbstract. Background We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma.
The new england journal of medicine established in 112 september 2, 6 vol. 355 no. 13 Sentinel-Node Biopsy or Nodal in Melanoma Donald L. Morton, M.D., John F. Thompson, M.D., Alistair J. Cochran, M.D.,
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationThin Melanoma. N Context. The incidence of malignant melanoma is
Thin Melanoma David E. Elder, MB ChB, FRCPA N Context. The incidence of malignant melanoma is increasing and a preponderance of the melanomas diagnosed today are thin in terms of Breslow criteria. Although
More informationAmelanotic melanoma of the skin detailed review of the problem
of the skin detailed review of the problem Strahil Strashilov 1, Veselin Kirov 2, Angel Yordanov 3, Yoana Simeonova 4 and Miroslava Mihailova 5 1. Department of Plastic Restorative, Reconstructive and
More informationResults, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de
University of Groningen Results, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de IMPORTANT NOTE: You are advised to consult the publisher's
More informationSentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner
Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationIncreasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma
Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma A. J. Page, Emory University A. Li, Emory University
More informationSentinel Node in Malignant Melanoma The Pathologist s Point of View
Sentinel Node in Malignant Melanoma The Pathologist s Point of View S.J. Diaz-Cano Department of Pathology, Barts and The London School of Medicine, University of London, Barts and The London NHS Trust,
More informationNEW SURGICAL APPROACHES TO MELANOMA THERAPY
NEW SURGICAL APPROACHES TO MELANOMA THERAPY Melanoma 2003: New Insights Into Therapy & Treatment Douglas L. Fraker, M.D. University of Pennsylvania Surgical Treatment of Melanoma Primary resection margins
More information> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
More informationPrognostic Variables and Surgical Management of Foot Melanoma: Review of a 25-Year Institutional Experience
Virginia Commonwealth University VCU Scholars Compass Surgery Publications Dept. of Surgery 11 Prognostic Variables and Surgical Management of Foot Melanoma: Review of a 5-Year Institutional Experience
More informationMultiple Primary Melanoma in a Thai Male: A Case Report
Case Report Multiple Primary Melanoma in a Thai Male: A Case Report J Med Assoc Thai 2014; 97 (Suppl. 2): S234-S238 Full text. e-journal: http://www.jmatonline.com Kittisak Payapvipapong MD*, Pinyapat
More informationMorphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
More informationPredictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma
ORIGINAL RESEARCH SURGERY // ANATOMO-PATHOLOGY Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma Călin Crăciun, Orsolya Hankó- Bauer, Zalán Benedek, Sorin Sorlea, Marius
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationIs There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?
Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1
More informationORIGINAL ARTICLE. Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection
ORIGINAL ARTICLE Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection Nir Nathansohn, MD, MHA; Jacob Schachter, MD; Haim Gutman, MD Hypothesis: Previous interventions (excisional
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationRecent Advances in Melanoma Staging and Therapy
Annals of Surgical Oncology, 6(5):467 475 Published by Lippincott Williams & Wilkins 1999 The Society of Surgical Oncology, Inc. Recent Advances in Melanoma Staging and Therapy Kelly M. McMasters, MD,
More informationSentinel Node Localisation of Melanoma
Sentinel Node Localisation of Melanoma V Bongers, Diakonessenhuis, Utrecht 1. Introduction A melanoma is mostly a malignancy of the skin. The sentinel lymph node (SLN) concept of sequential progression
More informationKentaro Tanaka, 1 Hiroki Mori, 1 Mutsumi Okazaki, 1 Aya Nishizawa, 2 and Hiroo Yokozeki Introduction. 2. Case Presentation
Case Reports in Oncological Medicine Volume 2013, Article ID 259326, 4 pages http://dx.doi.org/10.1155/2013/259326 Case Report Long-Term Treatment Outcome after Only Popliteal Lymph Node Dissection for
More informationDisclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationAn estimated 76,690 patients will be diagnosed with invasive
SONDAK ET AL Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma Vernon K. Sondak, MD, Sandra L. Wong, MD, Jeffrey E. Gershenwald, MD, and John F. Thompson,
More informationAssociated Detection Patterns, Lesion Characteristics, and Patient Characteristics
1562 Thin Primary Cutaneous Melanomas Associated Detection Patterns, Lesion Characteristics, and Patient Characteristics Jennifer L. Schwartz, M.D. 1 Timothy S. Wang, M.D. 1 Ted A. Hamilton, M.S. 1 Lori
More informationAnalysis of Lymph Nodal Metastases in Malignant Melanoma Using the Poisson Probability Paradigm and Bayes Rule
Anatomic Pathology / POISSON PARADIGM AND METASTATIC MELANOMA Analysis of Lymph Nodal Metastases in Malignant Melanoma Using the Poisson Probability Paradigm and Bayes Rule Robin T. Vollmer, MD Key Words:
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationIndex. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035
Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, 947 948 Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationMALIGNANT MELANOMA OF THE HEEL
MALIGNANT MELANOMA OF THE HEEL Pages with reference to book, From 50 To 53 Fazli M. Qazi ( Departments of Pathology, Khyber Medical College, Peshawar. ) Rahjm Gul ( Departments of Surgery, Khyber Medical
More informationInteresting Case Series. Desmoplastic Melanoma
Interesting Case Series Desmoplastic Melanoma Anthony Maurice Kordahi, MD, Joshua B. Elston, MD, Ellen M. Robertson, MD, and C. Wayne Cruse, MD Division of Plastic Surgery, Department of Surgery, University
More informationIs Sentinel Node Biopsy Practical?
Breast Cancer Is Sentinel Node Biopsy Practical? Benefits and Limitations JMAJ 45(10): 444 448, 2002 Shigeru IMOTO *1, Satoshi EBIHARA *2 and Noriyuki MORIYAMA *3 *1 Breast Surgery Division, National Cancer
More informationJohan Lyth, J Hansson, C Ingvar, E Mansson-Brahme, P Naredi, U Stierner, G Wagenius and C Lindholm. Linköping University Post Print
Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark s level of invasion: results of a population-based study from the Swedish Melanoma Register Johan
More informationDesmoplastic Melanoma: Clinical Behavior and Management Implications
Desmoplastic Melanoma: Clinical Behavior and Management Implications Collier S. Pace, MD, a Jyoti P. Kapil, MD, b Luke G. Wolfe, MS, c Brian J. Kaplan, MD, c and James P. Neifeld, MD c a Division of Plastic
More informationORIGINAL ARTICLE. Cervical Sentinel Lymph Node Biopsy for Melanomas of the Head and Neck and Upper Thorax
ORIGINAL ARTICLE Cervical Sentinel Lymph Node Biopsy for Melanomas of the Head and Neck and Upper Thorax Jeffrey D. Wagner, MD; Hee-Myung Park, MD; John J. Coleman III, MD; Charlene Love, RN; John T. Hayes,
More informationYou Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018
You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:
More informationSentinel Lymph Node Biopsy for Melanoma: Indications and Rationale
Sentinel lymph node biopsy is recommended for most patients with melanomas 0.76 mm and for all good surgical candidates with melanomas 1.0 mm. Catherine Hickson. Figs in Alizarin Crimson. Oil on Belgian
More informationTumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?
Ann Surg Oncol (2015) 22:2978 2987 DOI 10.1245/s10434-014-4349-3 ORIGINAL ARTICLE MELANOMAS Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? A Single-Institution Database
More informationSentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma
Sentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma John A Zitelli MD Adjunct Clinical Associate Professor Dermatology, Otolaryngology, Plastic Surgery University of Pittsburgh
More informationClinical and Pathological Features of Cutaneous Malignant Melanoma: A Retrospective Analysis of 124 Japanese Patients
Clinical and Pathological Features of Cutaneous Malignant Melanoma: A Retrospective Analysis of 24 Japanese Patients Yoshie Kuno, Kazuyuki Ishihara, Naoya Yamazaki and Kiyoshi Mukai 2 'Dermatology Division
More informationTherapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,
More informationSurgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick)
1941 Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick) Long-Term Results of a Large European Multicentric Phase III Study David Khayat, M.D., Ph.D.
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationLong-Term Survival Analysis and Clinical Follow-Up in Acral Lentiginous Malignant Melanoma Undergoing Sentinel Lymph Node Biopsy in Korean Patients
Ann Dermatol Vol. 26, No. 2, 2014 http://dx.doi.org/10.5021/ad.2014.26.2.177 ORIGINAL ARTICLE Long-Term Survival Analysis and Clinical Follow-Up in Acral Lentiginous Malignant Melanoma Undergoing Sentinel
More informationSentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins
Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in
More informationPregnancy and Early-Stage Melanoma. BACKGROUND. Cutaneous melanomas are aggressive tumors with an unpredictable
2248 Pregnancy and Early-Stage Melanoma Deepu Daryanani, M.D. 1 John T. Plukker, M.D., Ph.D. 1 Joanne A. De Hullu, M.D., Ph.D. 2 Hilde Kuiper, M.D. 3 Raoul E. Nap, M.Sc. 1 Harald J. Hoekstra, M.D., Ph.D.
More informationCase : A 49-Year-Old Woman with a Pigmented Lesion on the Arm
T h e n e w e ng l a nd j o u r na l o f m e dic i n e case records of the massachusetts general hospital Founded by Richard C. Cabot Nancy Lee Harris, m.d., Editor Eric S. Rosenberg, m.d., Associate Editor
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationPrognostic value of tumour thickness in cutaneous malignant melanoma
J Clin Pathol 1983;36:51-56 Prognostic value of tumour thickness in cutaneous malignant melanoma IONA JEFFREY, PATRICK ROYSTON, CHRISTOPHER SOWTER, GERARD SLAVIN, ASHLEY PRICE, ARIELA POMERANCE,* SALEEM
More informationMelanoma in the Older Person
Review Article [1] August 01, 2004 Melanoma [2], Older Patients [3], Oncology Journal [4] By Susan M. Swetter, MD [5], Alan C. Geller, MPH, RN [6], and John M. Kirkwood, MD [7] Melanoma incidence and mortality
More informationPrognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Otmar Elsaeßer 1., Ulrike Leiter 1 *., Petra G. Buettner 2, Thomas K. Eigentler 1, Friedegund Meier 1, Benjamin Weide 1, Gisela
More informationMalignant Melanoma among Older Adults
Cancer Malignant Melanoma among Older Adults Wey Leong, MSc, MD, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, ON. Alexandra M. Easson,
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationMalignant Melanoma of the Head and Neck: A Brief Review of Pathophysiology, Current Staging, and Management
The Ochsner Journal 8:181 185, 2008 f Academic Division of Ochsner Clinic Foundation Malignant Melanoma of the Head and Neck: A Brief Review of Pathophysiology, Current Staging, and Management Christian
More informationSurgical Oncology Perspective of Melanoma
Surgical Oncology Perspective of Melanoma Hans F. Schoellhammer, MD, FACS Assistant Clinical Professor Division of Surgical Oncology September 20, 2018 Nothing to disclose DISCLOSURE Discussion Objectives
More informationABSTRACT. Background Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial.
The new england journal of medicine established in 1812 february 13, 214 vol. 37 no. 7 Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma D.L. Morton, J.F. Thompson, A.J. Cochran,
More information